Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Andre T, et al. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. N Engl J Med. 2024. PMID: 39602630 Clinical Trial.
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. Siena S, et al. Among authors: masuishi t. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Nat Commun. 2024. PMID: 39587050 Free PMC article. Clinical Trial.
Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort.
Oshima T, Yamamoto S, Kawakami H, Makino T, Kawazoe A, Masuishi T, Tsushima T, Hirao M, Tsuda M, Hino K, Yamamoto N, Hara H, Kaname S, Matsuoka D, Otake Y, Yasuda K, Takase T, Takashima S, Semba T, Ooki A. Oshima T, et al. Among authors: masuishi t. BJC Rep. 2024 Sep 4;2(1):66. doi: 10.1038/s44276-024-00066-6. BJC Rep. 2024. PMID: 39516370 Free PMC article.
Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study.
Nakata A, Hashimoto N, Narita Y, Wakabayashi M, Kodama H, Ogata T, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ando M, Endo Y, Kotani H, Kataoka A, Hattori M, Yoshimura A, Sawaki M, Nozawa K, Oze I, Iwata H, Muro K. Nakata A, et al. Among authors: masuishi t. Oncologist. 2024 Sep 11:oyae223. doi: 10.1093/oncolo/oyae223. Online ahead of print. Oncologist. 2024. PMID: 39265970 Free article.
Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.
Takashima A, Ishiguro M, Sasaki K, Machida R, Nagashima F, Imaizumi J, Hamaguchi T, Yamamoto Y, Masuishi T, Asayama M, Ueno H, Shinozaki K, Kudo T, Machida N, Matsuoka H, Ishida H, Yamaguchi T, Nogami H, Yamada T, Takegawa N, Kito Y, Tonoike Y, Sawada R, Tsukamoto S, Kanemitsu Y; Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG). Takashima A, et al. Among authors: masuishi t. Jpn J Clin Oncol. 2024 Oct 3;54(10):1107-1114. doi: 10.1093/jjco/hyae110. Jpn J Clin Oncol. 2024. PMID: 39210583
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).
Takashima A, Hamaguchi T, Mizusawa J, Nagashima F, Ando M, Ojima H, Denda T, Watanabe J, Shinozaki K, Baba H, Asayama M, Hasegawa S, Masuishi T, Nakata K, Tsukamoto S, Katayama H, Nakamura K, Fukuda H, Kanemitsu Y, Shimada Y; Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG). Takashima A, et al. Among authors: masuishi t. J Clin Oncol. 2024 Nov 20;42(33):3967-3976. doi: 10.1200/JCO.23.02722. Epub 2024 Aug 26. J Clin Oncol. 2024. PMID: 39186709 Clinical Trial.
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y. Iida N, et al. Among authors: masuishi t. Clin Cancer Res. 2024 Sep 13;30(18):4167-4178. doi: 10.1158/1078-0432.CCR-24-1023. Clin Cancer Res. 2024. PMID: 39163021 Free PMC article.
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.
Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, Yoshino T, Kato T, Tsuji A. Bando H, et al. Among authors: masuishi t. Med. 2024 Sep 13;5(9):1164-1177.e3. doi: 10.1016/j.medj.2024.05.012. Epub 2024 Jun 19. Med. 2024. PMID: 38901425 Free article. Clinical Trial.
105 results